上海市北新股份有限公司.pptVIP

Progression as an endpoint in CRC;Progression is a meaningful endpoint in CRC trials;Tomudex vs. 5FU-LV in 1st line CRC;PFS and survival outcomes in the Tomudex trials;Evidence PFS is a surrogate for survival in the Tomudex program ;Log HR for PFS;Evidence PFS is a surrogate for survival in the Tomudex program ;Log HR for PFS;PFS and survival data from recently completed trials in 1st line CRC;Visit 1;Using overall ‘event count’ to comparetreatments for progression outcome1,2,3;Follow-up time (weeks);Summary